$CUE
Cue Biopharma, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022024991 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $151.2K $68.00K $2.395M
YoY Change -98.17% -97.16% 242.14%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.704M $3.528M $4.100M
YoY Change -20.3% -13.95% 24.62%
% of Gross Profit
Research & Development $11.33M $7.571M $11.00M
YoY Change 1.05% -31.15% 46.3%
% of Gross Profit
Depreciation & Amortization $203.2K $198.0K $316.0K
YoY Change -34.37% -37.34% 58.79%
% of Gross Profit
Operating Expenses $15.04M $11.10M $15.41M
YoY Change -6.89% -27.99% 42.25%
Operating Profit -$11.03M -$13.02M
YoY Change -15.26% 28.5%
Interest Expense $292.1K $124.0K $25.00K
YoY Change 7388.46% 396.0% -79.67%
% of Operating Profit
Other Income/Expense, Net $76.00K $25.00K
YoY Change 204.0% -75.0%
Pretax Income -$14.59M -$10.96M -$12.99M
YoY Change 84.97% -15.69% 29.53%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$14.59M -$10.96M -$12.99M
YoY Change 74.05% -15.69% 29.53%
Net Earnings / Revenue -9649.13% -16110.29% -542.51%
Basic Earnings Per Share -$0.31 -$0.41
Diluted Earnings Per Share -$0.37 -$0.31 -$412.3K
COMMON SHARES
Basic Shares Outstanding 35.39M 35.38M 31.32M
Diluted Shares Outstanding 35.38M 31.32M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $76.29M $59.18M $67.63M
YoY Change 18.51% -12.49% -26.45%
Cash & Equivalents $51.61M $29.73M $67.63M
Short-Term Investments $24.67M $29.46M $0.00
Other Short-Term Assets $841.2K $1.721M $1.851M
YoY Change -11.89% -7.02% 42.38%
Inventory
Prepaid Expenses
Receivables $57.25K $796.0K $771.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $77.19M $61.70M $70.26M
YoY Change 12.74% -12.18% -24.94%
LONG-TERM ASSETS
Property, Plant & Equipment $1.499M $1.642M $5.708M
YoY Change -29.01% -71.23% 228.23%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $128.3K $131.0K $2.912M
YoY Change -8.33% -95.5% -14.35%
Total Long-Term Assets $14.10M $14.60M $8.620M
YoY Change -5.61% 69.37% -33.69%
TOTAL ASSETS
Total Short-Term Assets $77.19M $61.70M $70.26M
Total Long-Term Assets $14.10M $14.60M $8.620M
Total Assets $91.28M $76.30M $78.88M
YoY Change 9.45% -3.26% -26.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.731M $2.045M $2.470M
YoY Change 5.41% -17.21% 124.55%
Accrued Expenses $3.554M $3.879M $7.622M
YoY Change -23.07% -49.11% 5.86%
Deferred Revenue
YoY Change
Short-Term Debt $73.97K $37.00K $0.00
YoY Change
Long-Term Debt Due $2.000M $1.000M
YoY Change
Total Short-Term Liabilities $11.55M $10.22M $15.36M
YoY Change -9.69% -33.43% 8.13%
LONG-TERM LIABILITIES
Long-Term Debt $8.035M $8.993M $0.00
YoY Change
Other Long-Term Liabilities $6.018M $6.321M $0.00
YoY Change 17.5% -100.0%
Total Long-Term Liabilities $8.035M $8.993M $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.55M $10.22M $15.36M
Total Long-Term Liabilities $8.035M $8.993M $0.00
Total Liabilities $25.60M $25.54M $15.36M
YoY Change 42.95% 66.3% -19.61%
SHAREHOLDERS EQUITY
Retained Earnings -$250.5M -$235.9M -$189.1M
YoY Change 26.85% 24.75%
Common Stock $316.2M $286.7M
YoY Change 20.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $65.68M $50.76M $63.52M
YoY Change
Total Liabilities & Shareholders Equity $91.28M $76.30M $78.88M
YoY Change 9.45% -3.26% -26.01%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$14.59M -$10.96M -$12.99M
YoY Change 74.05% -15.69% 29.53%
Depreciation, Depletion And Amortization $203.2K $198.0K $316.0K
YoY Change -34.37% -37.34% 58.79%
Cash From Operating Activities -$10.51M -$6.871M -$6.627M
YoY Change -1.23% 3.68% -13.82%
INVESTING ACTIVITIES
Capital Expenditures $750.00 -$78.00K -$13.00K
YoY Change -1975.0% 500.0% -96.29%
Acquisitions
YoY Change
Other Investing Activities $5.000M -$29.44M $2.000K
YoY Change 908967.27% -1472200.0% -99.96%
Cash From Investing Activities $4.999M -$29.52M -$11.00K
YoY Change 980119.61% 268263.64% -100.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 27.40M -9.000K 351.0K
YoY Change 271.2% -102.56% -97.66%
NET CHANGE
Cash From Operating Activities -10.51M -6.871M -6.627M
Cash From Investing Activities 4.999M -29.52M -11.00K
Cash From Financing Activities 27.40M -9.000K 351.0K
Net Change In Cash 21.89M -36.40M -6.287M
YoY Change -770.94% 478.97% -152.52%
FREE CASH FLOW
Cash From Operating Activities -$10.51M -$6.871M -$6.627M
Capital Expenditures $750.00 -$78.00K -$13.00K
Free Cash Flow -$10.51M -$6.793M -$6.614M
YoY Change -1.23% 2.71% -9.89%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001645460
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38327
dei Entity Registrant Name
EntityRegistrantName
Cue Biopharma, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3324577
dei Entity Address Address Line1
EntityAddressAddressLine1
40 Guest Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02135
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
949-2680
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
CUE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35385582
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29726000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64371000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
29457000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
796000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3143000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1721000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
955000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
61700000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
68469000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1642000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2112000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9561000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9810000
CY2022Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
3116000
CY2021Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
2721000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
150000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
150000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
131000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
140000
CY2022Q3 us-gaap Assets
Assets
76300000
CY2021Q4 us-gaap Assets
Assets
83401000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2045000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2591000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3879000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4620000
CY2022Q3 cue Research And Development Contract Liability Current
ResearchAndDevelopmentContractLiabilityCurrent
0
CY2021Q4 cue Research And Development Contract Liability Current
ResearchAndDevelopmentContractLiabilityCurrent
645000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3335000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4932000
CY2022Q3 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
963000
CY2021Q4 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
0
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
10222000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12788000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6321000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5121000
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8993000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2022Q3 us-gaap Liabilities
Liabilities
25536000
CY2021Q4 us-gaap Liabilities
Liabilities
17909000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35385582
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35385582
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32202496
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32202496
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
35000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
32000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6687000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
286685000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
262906000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-92000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-235864000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-197446000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
50764000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
65492000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
76300000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
83401000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
68000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2395000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1094000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3528000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4125000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12465000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12660000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7571000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11288000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27246000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29846000
CY2022Q3 cue Gain On Right Of Use Asset Termination
GainOnRightOfUseAssetTermination
0
CY2021Q3 cue Gain On Right Of Use Asset Termination
GainOnRightOfUseAssetTermination
0
cue Gain On Right Of Use Asset Termination
GainOnRightOfUseAssetTermination
258000
cue Gain On Right Of Use Asset Termination
GainOnRightOfUseAssetTermination
0
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
11099000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
15413000
us-gaap Operating Expenses
OperatingExpenses
39453000
us-gaap Operating Expenses
OperatingExpenses
42506000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-11031000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13018000
us-gaap Operating Income Loss
OperatingIncomeLoss
-38359000
us-gaap Operating Income Loss
OperatingIncomeLoss
-35819000
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
200000
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
25000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
296000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
42000
CY2022Q3 us-gaap Interest Expense
InterestExpense
124000
CY2021Q3 us-gaap Interest Expense
InterestExpense
0
us-gaap Interest Expense
InterestExpense
355000
us-gaap Interest Expense
InterestExpense
0
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
76000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
25000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-59000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
42000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-10955000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-12993000
us-gaap Net Income Loss
NetIncomeLoss
-38418000
us-gaap Net Income Loss
NetIncomeLoss
-35777000
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-92000
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-92000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-7000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11047000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12993000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38510000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35784000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.41
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.41
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.16
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.16
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35383430
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35383430
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31315178
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31315178
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34471499
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34471499
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31064579
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31064579
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
72910000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3252000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
834000
CY2021Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-1000
CY2021Q3 cue Restricted Stock Awards Withheld At Vesting To Cover Taxes Amount
RestrictedStockAwardsWithheldAtVestingToCoverTaxesAmount
-482000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-12993000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
63520000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
59756000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2064000
CY2022Q3 cue Restricted Stock Awards Withheld At Vesting To Cover Taxes Amount
RestrictedStockAwardsWithheldAtVestingToCoverTaxesAmount
-9000
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-92000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-10955000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
50764000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
78911000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10357000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8541000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2062000
cue Restricted Stock Awards Withheld At Vesting To Cover Taxes Amount
RestrictedStockAwardsWithheldAtVestingToCoverTaxesAmount
-567000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-7000
us-gaap Net Income Loss
NetIncomeLoss
-35777000
cue Restricted Stock Awards Withheld At Vesting To Cover Taxes Amount
RestrictedStockAwardsWithheldAtVestingToCoverTaxesAmount
-200000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
63520000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
65492000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16598000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7384000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
-92000
us-gaap Net Income Loss
NetIncomeLoss
-38418000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
50764000
us-gaap Profit Loss
ProfitLoss
-38418000
us-gaap Profit Loss
ProfitLoss
-35777000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
719000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
948000
us-gaap Share Based Compensation
ShareBasedCompensation
7384000
us-gaap Share Based Compensation
ShareBasedCompensation
8541000
cue Change In Operating Lease Right Of Use Asset
ChangeInOperatingLeaseRightOfUseAsset
507000
cue Change In Operating Lease Right Of Use Asset
ChangeInOperatingLeaseRightOfUseAsset
3405000
us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
258000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-4000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
21000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-101000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-5000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
21000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0
cue Accretion Of Final Payment On Term Loan
AccretionOfFinalPaymentOnTermLoan
76000
cue Accretion Of Final Payment On Term Loan
AccretionOfFinalPaymentOnTermLoan
0
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2347000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-646000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
846000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
867000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-250000
cue Increase Decrease In Deposit Liabilities
IncreaseDecreaseInDepositLiabilities
-395000
cue Increase Decrease In Deposit Liabilities
IncreaseDecreaseInDepositLiabilities
-47000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-546000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
400000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-741000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1202000
cue Increase Decrease In Research And Development Contract Liability
IncreaseDecreaseInResearchAndDevelopmentContractLiability
-645000
cue Increase Decrease In Research And Development Contract Liability
IncreaseDecreaseInResearchAndDevelopmentContractLiability
-3354000
cue Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-397000
cue Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-3513000
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
3000
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31292000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28192000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
170000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
913000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
6000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
21000
cue Payments For Redemption Of Short Term Investments
PaymentsForRedemptionOfShortTermInvestments
0
cue Payments For Redemption Of Short Term Investments
PaymentsForRedemptionOfShortTermInvestments
-10000000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
29445000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29609000
cue Proceeds From At Time Market Offering Net Of Commission And Fees
ProceedsFromAtTimeMarketOfferingNetOfCommissionAndFees
16598000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
9108000
cue Proceeds From At Time Market Offering Net Of Commission And Fees
ProceedsFromAtTimeMarketOfferingNetOfCommissionAndFees
10357000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
10000000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2061000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
142000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
200000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
567000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
26256000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11851000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-34645000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7233000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
64521000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
75016000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
29876000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
67783000
us-gaap Income Taxes Paid
IncomeTaxesPaid
0
us-gaap Income Taxes Paid
IncomeTaxesPaid
206000
us-gaap Interest Paid Net
InterestPaidNet
354000
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
9057000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
cue Operating Lease Modification
OperatingLeaseModification
7119000
cue Operating Lease Modification
OperatingLeaseModification
0
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2014-12-31
CY2022Q3 us-gaap Marketable Securities
MarketableSecurities
59183000
cue Amortization Of Trademark
AmortizationOfTrademark
9000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include estimates related to collaboration revenue, the accounting for potential liabilities and accrued expenses, the assumptions utilized in valuing stock-based compensation issued for services, the realization of deferred tax assets, and the useful life with respect to long-lived assets and intangibles. Actual results could differ from those estimates.</span></p>
cue Amortization Of Capitalized License Expense
AmortizationOfCapitalizedLicenseExpense
257000
us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P15Y
CY2022Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2022Q3 us-gaap Debt Securities Trading And Available For Sale
DebtSecuritiesTradingAndAvailableForSale
29457000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
0
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7058087
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6517295
CY2022Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
23256000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
29457000
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
52509000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2022Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
23256000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
29457000
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
52509000
CY2022Q3 cue Fair Value Assets Among Level2 And Level3 Transfers Amount
FairValueAssetsAmongLevel2AndLevel3TransfersAmount
0
CY2021Q4 cue Fair Value Assets Among Level2 And Level3 Transfers Amount
FairValueAssetsAmongLevel2AndLevel3TransfersAmount
0
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
29457000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2022Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
29550000
CY2021Q4 us-gaap Debt Securities Trading And Available For Sale
DebtSecuritiesTradingAndAvailableForSale
0
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2112000
CY2022Q3 us-gaap Depreciation
Depreciation
198000
CY2021Q3 us-gaap Depreciation
Depreciation
232000
us-gaap Depreciation
Depreciation
630000
us-gaap Depreciation
Depreciation
682000
cue Amortization Of Trademark
AmortizationOfTrademark
9000
cue Amortization Of Capitalized License Expense
AmortizationOfCapitalizedLicenseExpense
80000
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5695000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5556000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4054000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3444000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1642000
CY2022Q3 us-gaap Long Term Debt
LongTermDebt
9000000
CY2022Q3 cue Accretion Of Final Payment
AccretionOfFinalPayment
76000
CY2022Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
-83000
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8993000
CY2022Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
1000000
CY2022Q3 us-gaap Deferred Finance Costs Current Gross
DeferredFinanceCostsCurrentGross
37000
CY2022Q3 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
963000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
0
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2000000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
4000000
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
4000000
CY2022Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10000000
CY2022Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
142000
CY2022Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
9000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
21000
CY2022Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
37000
CY2022Q3 us-gaap Other Long Term Debt
OtherLongTermDebt
83000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0153
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0292
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.921
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.957
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0061
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0131
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.978
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.009
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5654168
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.08
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y5M23D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
828500
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.99
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
213939
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
13.32
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6268729
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.56
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y2M19D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4358165
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
8.97
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y9M14D
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
13856000
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
18124000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
35000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
12.24
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1026000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
14.41
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
4358000
CY2022Q3 cue Share Based Compensation Arrangement By Share Based Payment Award Fair Value Of Options Exercisable Intrinsic Fair Value Per Share
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsExercisableIntrinsicFairValuePerShare
8.97
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2064000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3252000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7384000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8541000
cue Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Of Common Stock
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueOfCommonStock
2.23
CY2015Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1500
CY2022Q3 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2015-06-15
CY2015Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.70
CY2020Q4 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1250000
CY2021Q4 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
3000000
CY2015Q2 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P7Y
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
851969
cue Class Of Warrants Or Rights Cashless Issue Exercises
ClassOfWarrantsOrRightsCashlessIssueExercises
9549
cue Class Of Warrant Or Right Number Of Securities Withheld
ClassOfWarrantOrRightNumberOfSecuritiesWithheld
51562
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1500
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
789358
CY2022Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
2500000
cue Milestone Payments Received
MilestonePaymentsReceived
2800000
CY2019Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
2500000
us-gaap Description Of Lessee Leasing Arrangements Operating Leases
DescriptionOfLesseeLeasingArrangementsOperatingLeases
Upon execution of the Laboratory and Office Lease, the Company prepaid three months of rent, two of which will be held in escrow and credited against future rent payments and the other of which was applied to the first month’s rent. The Company also prepaid seven and one-half months’ rent pursuant to an amendment to the lease agreement executed on June 18, 2018. These amounts were recorded to deposits and prepaid expenses, respectively, at December 31, 2018
CY2022Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
146000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
309000
CY2022Q3 us-gaap Security Deposit Liability
SecurityDepositLiability
794000
CY2022Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
822000
CY2022Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
3366000
CY2022Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2857000
CY2022Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2799000
CY2022Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
818000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
10662000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
897000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
9765000
CY2022Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
860000
CY2021Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1223000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
3309000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
3668000
CY2022Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
297000
us-gaap Operating Lease Payments
OperatingLeasePayments
397000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
860000
us-gaap Operating Lease Cost
OperatingLeaseCost
3309000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M14D
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M14D

Files In Submission

Name View Source Status
0000950170-22-024991-index-headers.html Edgar Link pending
0000950170-22-024991-index.html Edgar Link pending
0000950170-22-024991.txt Edgar Link pending
0000950170-22-024991-xbrl.zip Edgar Link pending
cue-20220930.htm Edgar Link pending
cue-20220930.xsd Edgar Link pending
cue-ex10_1.htm Edgar Link pending
cue-ex31_1.htm Edgar Link pending
cue-ex31_2.htm Edgar Link pending
cue-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img76103294_0.jpg Edgar Link pending
img76103294_1.jpg Edgar Link pending
img76103294_2.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
cue-20220930_def.xml Edgar Link unprocessable
cue-20220930_lab.xml Edgar Link unprocessable
cue-20220930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cue-20220930_htm.xml Edgar Link completed
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cue-20220930_cal.xml Edgar Link unprocessable